Balance Sheet
AssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Current Assets (2019 - 2025)

Benitec Biopharma's Current Assets history spans 5 years, with the latest figure at $78.7 million for Q4 2024.

  • For Q4 2024, Current Assets rose 278.5% year-over-year to $78.7 million; the TTM value through Dec 2024 reached $78.7 million, up 278.5%, while the annual FY2024 figure was $51.7 million, 1285.73% up from the prior year.
  • Current Assets for Q4 2024 was $78.7 million at Benitec Biopharma, up from $68.3 million in the prior quarter.
  • Across five years, Current Assets topped out at $78.7 million in Q4 2024 and bottomed at $3.7 million in Q2 2023.
  • The 5-year median for Current Assets is $17.1 million (2022), against an average of $26.1 million.
  • The largest annual shift saw Current Assets plummeted 76.61% in 2022 before it skyrocketed 1285.73% in 2024.
  • A 5-year view of Current Assets shows it stood at $10.8 million in 2020, then soared by 51.47% to $16.4 million in 2021, then increased by 4.33% to $17.1 million in 2022, then rose by 21.75% to $20.8 million in 2023, then surged by 278.5% to $78.7 million in 2024.
  • Per Business Quant, the three most recent readings for BNTC's Current Assets are $78.7 million (Q4 2024), $68.3 million (Q3 2024), and $51.7 million (Q2 2024).